Conférences  >  Médecine & Soins de Santé  >  Pharmacologie et développement des médicaments

Uventia Global

The Visual Inspection in Parenterals summit is a premier event that brings together experts from the pharmaceutical and biotechnology sectors to explore best practices, technologies and advancements in the visual inspection of parenteral products. Parenterals, which include injectable drugs and biologics, require stringent quality control measures to ensure their safety and efficacy. This conference will cover a wide range of topics such as the latest innovations in automated and manual visual inspection techniques, detection of particulate matter, container-closure integrity and regulatory requirements. Attendees will gain insights into cutting-edge technologies, industry standards and case studies aimed at enhancing the accuracy and reliability of visual inspections. The event will also provide valuable networking opportunities for professionals to collaborate and share expertise, fostering improvements in product quality and patient safety. This conference is essential for anyone involved in the manufacturing, testing and regulation of parenteral products.

Email.: info@uventia.com

Regulatory and Compendial Requirements for Visual Inspection, Lifecycle Approach in Visual Inspection and Particle Management, Risk-Based Validation Case Studies, Inspector Training and Qualification, Deep Learning (DL) and Artificial Intelligence (AI) for Visual Inspection, Defect Classifications: Categorizing Defects and Nonconformities, Particulate Matter: Classification, Characterization & Control, Container Integrity Inspection and Leak Detection, New solutions for quality control of difficult to inspect parenterals

Législation en médecine et pharmacologie,    Biotechnologie

FDAMap

Manufacturing an investigational product for the initial pilot clinical trials can be a complex and costly endeavor for developers. These first-in-man and pilot clinical trials, usually conducted with a small number of healthy participants, are primarily aimed at establishing safety. Therefore, they do not require a significant amount of investigational material. Recognizing this, the US FDA allows developers to test early-stage investigational products under relaxed GMP requirements.

FDA, Gmp, Clinical Trials, FDA Regulations, FDA Compliance,

Législation en médecine et pharmacologie,    Médecine translationnelle, essais cliniques

FDAMap

Many pharmaceutical, biotechnology, and medical device companies engage one or more Clinical Research Organizations (CROs) to conduct their clinical trials. However, managing a study through a CRO presents unique challenges compared to in-house operations, yet companies frequently lack formal training for this transition. Moreover, the recent update to the ICH Good Clinical Practice (GCP) guidelines underscores the Sponsor’s responsibility to actively oversee their trials. Regulatory agencies are increasingly scrutinizing this aspect, identifying it as a potential weakness within Sponsor companies. This workshop addresses these critical issues by providing comprehensive training on effective CRO oversight. Participants will gain the knowledge and skills necessary to navigate the complexities of managing CRO-run projects, ensuring regulatory compliance, and optimizing trial outcomes. Through interactive sessions and practical insights, attendees will learn how to enhance their oversight practices and strengthen their organization’s approach to clinical trial management.

Cro, Clinical Research Organizations, Good Clinical Practice, Clinical Trial Management

Législation en médecine et pharmacologie,    Médecine translationnelle, essais cliniques

European Society for Medical Oncology

ESMO TAT, the multi-stakeholder forum gathering key actors in cancer drug development, arrives in one of the most dynamic and best-connected hubs in Asia, making the latest advances in early clinical trials accessible to everyone in the region. Through in-depth discussions on critical topics such as innovation, digital transformation, research methodology, business insights, regulation, and public policy, ESMO TAT Asia aims to drive progress in cancer treatment and research. Located in the lively city of Hong Kong, ESMO TAT Asia promises to be a vibrant gathering with region’s industry, academia, clinicians, and regulators to promote international cooperation and accelerate the anticancer research. Come and join us to chart new paths in cancer drug development in Asia.

ESMO Asia TAT 2025 Secretariat;     Email.: asiacongress@esmo.org

targeted therapies, early drug development, cancer therapeutics, immunotherapy, cytotoxic therapy, cell therapy, biotech, pharmaceutical industry

FDAMap

Each year FDA receives about 3000 applications for new devices via the 510k process, and about 60% of them are rejected either for poor quality application that cannot even be reviewed or for other technical reasons. Submissions to the FDA that are poorly organized, do not follow current practices, contain inconsistencies between documents, have missing or incomplete content, or poor structure will result in significant delays in the clearance process. With multiple review cycles, up to 90 days each, rejections by FDA could stretch the 510k clearance time-lines to 8 months or more. Most of the refuse-to-accept deficiencies are due to the inexperience of the 510k writers, who ignore the FDA rules. Writing and assembling a complete and well structured 510(k) submission will certainly improve the likelihood of FDA clearance on the first round.

FDA, 510(k) Submissions, FDA Regulations, FDA Compliance

Législation en médecine et pharmacologie,    Médecine translationnelle, essais cliniques

CHI

Join a global community of thought leaders and innovators shaping the future of bioprocessing. Dive into cutting-edge research, share insights with industry experts, and tackle the challenges of bioprocess R&D, scale-up, quality, and analytics.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

CHI

In its 23rd year Discovery on Target is the premier event highlighting “hot” drug targets and emerging modalities, technologies and strategies for pursuing those targets. The numerous conferences, symposia, courses and training seminars offer key insights for the successful discovery and development of novel therapeutics, from small molecules to biologics to chimeras and conjugates. The 4 day event covers innovations in target identification and lead generation, which includes cancer therapies, protein degradation, induced proximity, AI/machine learning, membrane proteins, translational models, synthetic biology and other relevant topics. New this year is an increased coverage of GLP-1, MASH and obesity, ADCs and bispecifics and on small molecules targeting DNA.

Tél.: [781.972.5400];     Email.: chi@healthtech.com

Cancérologie,    Biotechnologie

World High Technology Society

The Annual Congress of International Drug Discovery Science & Technology (IDDST), initiated from 2003, has been successfully organized in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA), Kyoto (Japan), Tokyo (Japan), Amsterdam (the Netherlands), Osaka (Japan) and Budapest (Hungary) and has attracted more than 10000 participants from over 50 countries and regions in the previous 20 years. The 21th IDDST (Europe) will be held during June 18-20, 2025 at Stockholm, Sweden. It continues to expand with magnificent scientific and social programs to maximize your network in a free communication meeting environment.

The 21th IDDST (Europe) will host leading scientists from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. The program of the coming conference promises to be very interesting for both basic scientists and executives who are working in the field of drug discovery and other related areas, they will offer complete updates of recent developments and present the latest results in the remarkable separate tracks. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better practice and application.

Magnus Group

Prepare to immerse yourself in the 5th Edition of the International Vaccines Congress (IVC 2025), taking place from October 23-25, 2025, in the vibrant city of Orlando, Florida, USA! This highly anticipated International Vaccines Congress 2025 will offer a unique hybrid format, seamlessly blending onsite and online experiences to maximize global reach and participation. Dive deep into the latest advancements and transformative trends in vaccine science under the theme: From Discovery to Distribution: The Path of Vaccines.

Tél.: [17029882320];     Email.: vaccines@magnusconference.com

ELETS Technomedia

The expo will be taking place at Hitex Exhibition Centre from 23rd- 25th April (Thu-Sat) 2026, With the concurrent events Next Gen Pharma Summit and Healthcare Innovation Expo & Summit 2026.It will unite pharmaceutical companies, Drug manufacture, healthcare providers, policymakers, researchers, and technology leaders from around the world on one powerful platform to share knowledge, explore solutions, and foster strategic partnerships.

Tél.: [09560050693];     Email.: indiapharmaexpo1@gmail.com

Pharamaceuticals, Healthcare Technologies, Vaccines, Nanotechnology, Smart Molecule

Salons, foire-exposition,    Génie biomédical

The expo will be taking place t Hitex Exhibition Centre from 23rd- 25th April (Thu-Sat). 2026, with the concurrent events NextGenPharma Summit and Healthcare Innovation Expo & Summit 2026.It will unite pharmaceutical companies,Drug manufacture, healthcare providers, policymakers, researchers, and technology leaders from around the world on one powerful platform to share knowledge, explore solutions, and foster strategic partnerships.

Project Head;     Tél.: [95600 50693];     Email.: milan.jena@elets.in

healthcare, science, pharmaceuticals, biotenchnology, nenotechnology, health